ADAP Medical Advisory Committee

July 20, 2022 Gathering Notes

1) Welcome and Rollcall
   I. Welcome:
      Meeting opened by Sharisse Kemp, ADAP Branch Chief
   II. Introductions:
      MAC Members, CDPH and Magellan introduced themselves

MAC Members in Attendance

CDPH/Office of AIDS staff in Attendance
Philip Peters, Sharisse Kemp, Ann Nakamura, Becca Parks, James Vo, Alejandro Contreras

Magellan Representatives in Attendance
Jason Eugenio, Carrie Holden

2) ADAP / MAC Updates
   I. Medications added to the ADAP formulary:
      • Removal of the maximum 5-refill limit to non-controlled ADAP formulary medications.
      • Removal of Brand Preferencing for Epclusa and Harvoni.
      • Hypertension and diabetes medications are moving forward towards being added to the ADAP formulary.
      • Primaquine, Priftin and Xifaxan will be added to the ADAP formulary. A management memo will be released with more information.
   II. Medications removed from the ADAP formulary
      • None
   III. Update on the medications discussed during the March 2022 MAC meeting:
      • Ethinyl estradiol and norethindrone contraceptive medications to the ADAP formulary are currently in final stages of approval.

3) Medication Discussion
   I. No new ARVs have received FDA approval
II. No public comments received

4) **Opportunistic Infection Treatments**

I. No new opportunistic infection discussion

5) **Magellan Rx Presentation**

I. Carrie Holden presented on:

- Antipsychotics
- Diabetes Treatment

6) **Close of Meeting**

I. The next ADAP MAC gathering is scheduled for October 19, 2022, from 7:30 a.m. to 9:00 a.m.

7) **Action Items**

<table>
<thead>
<tr>
<th>Action Items</th>
<th>Owners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-acting injectable antipsychotic medications</td>
<td>Carrie Holden</td>
</tr>
<tr>
<td>Diabetes medication cost analysis</td>
<td>James Vo</td>
</tr>
<tr>
<td>Drafting a statement for prioritization of Monkeypox</td>
<td>James Vo</td>
</tr>
</tbody>
</table>